Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$2.50 – $4.84
27% from low
Exchange
OTC Link
OS
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $99.1M | $126.9M | $239.9M | $770.4M | $1.83B | $2.34B | $2.54B | $2.69B |
| Cost of revenue | $25.6M | $33.8M | $82.6M | $384.6M | $813.9M | $1.05B | $1.08B | $1.17B |
| Gross profit | $73.5M | $93.1M | $157.3M | $385.9M | $1.02B | $1.29B | $1.46B | $1.52B |
| Gross margin | 74.2% | 73.3% | 65.6% | 50.1% | 55.5% | 55.2% | 57.5% | 56.5% |
| R&D | $0 | $0 | $3.9M | $9.4M | $12.7M | $0 | $0 | $0 |
| Operating income | $29.4M | $36.9M | $60.4M | $64.6M | $120.0M | $173.2M | $225.0M | $140.6M |
| EBITDA | $30.6M | $40.1M | $54.9M | $138.9M | $390.0M | $484.3M | $548.6M | $468.2M |
| Net income | $23.3M | $29.9M | $48.5M | $54.6M | $94.5M | $58.6M | $98.9M | $55.5M |
| Net margin | 23.5% | 23.6% | 20.2% | 7.1% | 5.2% | 2.5% | 3.9% | 2.1% |
| EPS (diluted) | 0.30 | 0.38 | 0.56 | 0.49 | 0.61 | 0.37 | 0.62 | 0.35 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $2.8B | $1.17 | $1.15–$1.19 | 1 |
| 2027 | $3.1B | $1.71 | $1.69–$1.74 | 1 |
| 2028 | $3.3B | $2.17 | $2.14–$2.21 | 1 |
Forward consensus · source: Financial Modeling Prep
SWEDENCARE AB PUBL AK
No one on the platform currently holds SWDCF.
No tracked institution reports a position in SWDCF as of their last filing.
| Ex-date | Per share | Pay date |
|---|---|---|
| 2026-04-27 | $0.2800 | 2026-04-30 |
| 2025-04-28 | $0.2500 | 2025-05-02 |
| 2024-04-26 | $0.2300 | 2024-05-03 |
No one on the platform has traded SWDCF yet.
| $428M |
| — |
| ELTPElite Pharmaceuticals, Inc. | $0.40 | +0.00% | $431M | — |
| GLASFGlass House Brands Inc. | $12.34 | +1.06% | $974M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at 5.4× earnings vs its 10.8× historical median P/E.
Fair value ≈ $6.26 · price $3.13 today
Fair-value line = the stock's median historical P/E × earnings. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.